SEQUANA MEDICAL LAUNCHES EQUITY PLACEMENT
March 07, 2022 08:30 ET
|
Sequana Medical NV
THIS ANNOUNCEMENT IS NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD BE PROHIBITED...
Sequana Medical receives certification under MDR, the new European Medical Device Regulation
February 14, 2022 01:00 ET
|
Sequana Medical NV
alfapump® is one of the first novel Class III active implantable medical devices to be certified Ghent, Belgium – 14 February 2022 – Sequana Medical NV (Euronext Brussels: SEQUA, the “Company” or...
Sequana Medical to present at BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
February 03, 2022 01:00 ET
|
Sequana Medical NV
Ghent, Belgium – 3 February 2022 – Sequana Medical NV (Euronext Brussels: SEQUA, the “Company” or “Sequana Medical”), an innovator in the treatment of diuretic-resistant fluid overload in liver...
SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES
January 21, 2022 12:00 ET
|
Sequana Medical NV
PRESS RELEASEREGULATED INFORMATION21 January 2022, 06:00 pm CET Ghent, Belgium – 21 January 2022 – Sequana Medical NV (Euronext Brussels: SEQUA, the "Company" or "Sequana Medical"), an...
Sequana Medical to attend 11th Annual LifeSci Partners Corporate Access Event and H.C. Wainwright BIOCONNECT Virtual Conference
December 17, 2021 01:00 ET
|
Sequana Medical NV
CEO Ian Crosbie to participate in a panel discussion on “MedTech and digital tools: What is the Mindset for 2022?” Ghent, Belgium – 17 December 2021 – Sequana Medical NV (Euronext Brussels: SEQUA,...
Sequana Medical announces positive interim results of SAHARA DESERT, the alfapump DSR® study in heart failure patients with persistent congestion
December 07, 2021 01:00 ET
|
Sequana Medical NV
PRESS RELEASEREGULATED INFORMATION – INSIDE INFORMATION7 December 2021, 07:00 am CET Interim data from six patients indicate that alfapump DSR therapy can: safely, effectively and rapidly eliminate...
Sequana Medical announces the completion of patient enrolment in POSEIDON, the North American pivotal alfapump® study
December 06, 2021 01:00 ET
|
Sequana Medical NV
Positive interim analysis reported in July 2021Reporting of primary endpoint planned for Q4 2022 Ghent, Belgium – 6 December 2021 – Sequana Medical NV (Euronext Brussels: SEQUA, the “Company” or...
Sequana Medical to present at Jefferies London Healthcare Conference
November 09, 2021 01:00 ET
|
Sequana Medical NV
Ghent, Belgium – 9 November 2021 – Sequana Medical NV (Euronext Brussels: SEQUA, the “Company”), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites...
Sequana Medical receives MDSAP certification and expands its Quality Management System towards North America
November 03, 2021 02:00 ET
|
Sequana Medical NV
Ghent, Belgium – 3 November 2021 – Sequana Medical NV (Euronext Brussels: SEQUA, the “Company”), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant...
Sequana Medical announces FDA approval to expand patient enrolment in North American pivotal alfapump® study (POSEIDON)
October 04, 2021 01:00 ET
|
Sequana Medical NV
PRESS RELEASEREGULATED INFORMATION - INSIDE INFORMATION4 October 2021, 07:00 CET Completion of patient enrolment expected before end of year Primary endpoint read-out due in Q4 202259 patients...